Core Insights - The recent executive order by President Trump marks a significant step in cannabis policy reform, although it does not legalize cannabis, it facilitates medical research and alleviates the tax burden on companies in the industry [1][2] - The executive order is seen as a precursor to further legislative actions, particularly regarding safer banking for cannabis businesses, which could lead to greater access to capital and potential listings on major US exchanges like NASDAQ and NYSE [3][4] Industry Impact - The cannabis industry has faced significant challenges, including a 20% market sell-off following a 150% increase in five days, indicating volatility and market reactions to news [5] - There is a concern regarding the relationship between the cannabis and hemp markets, particularly in light of the new regulations and the need for a regulated marketplace [5][6] - The executive order emphasizes the importance of safe, regulated, and tested products, aligning with the existing medical cannabis programs in 40 states [7][8]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company is focused on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Points - Cannabis has been rescheduled from a Class 1 to a Class 3 substance under the Controlled Substances Act, marking a significant reform in its legal status [1][2] - The new law will enable the IRS to collaborate with legal cannabis businesses, providing them with tax breaks and incentives [1] - The bill aims to enhance cannabis research and redefine hemp to ensure full-spectrum CBD is accessible to patients [2] Industry Impact - The rescheduling is seen as a win for corporate cannabis, but it may pose challenges for smaller craft cannabis operators, potentially disrupting the coexistence of mom-and-pop brands in the industry [5] - Initial reactions in the marijuana stock market were muted, but there is potential for increased trading activity as investors fully digest the news [5] - The cannabis sector may experience a rise in stock prices as the week closes, depending on investor sentiment [5]

Core Viewpoint - President Donald Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, significantly impacting the cannabis industry and leading to a surge in US cannabis stocks [1] Group 1: Executive Order Impact - The executive order directs federal agencies to change the classification of marijuana, which could lead to increased research and development opportunities within the cannabis sector [1] - This reclassification is expected to reduce regulatory burdens on cannabis companies, potentially enhancing their operational capabilities and market access [1] Group 2: Market Reaction - Following the announcement, US cannabis stocks experienced a sharp increase, indicating strong investor optimism regarding the future of the cannabis market [1] - The market response reflects a growing acceptance of cannabis and its potential for commercialization, which may attract more investment into the sector [1]

Core Viewpoint - The president has signed an executive order to reclassify marijuana from a Schedule I drug to a Schedule III drug, indicating a shift towards less regulation and acknowledging the therapeutic potential of marijuana, particularly for patients with serious illnesses like cancer [1][2]. Industry Impact - The reclassification of marijuana is expected to have significant implications for the cannabis industry, potentially leading to increased investment and market activity as stocks have already begun to move positively in anticipation of this change [2]. Market Reaction - Following the announcement of the reclassification, cannabis stocks have been on the rise for about a week, indicating strong market interest and investor confidence in the sector's future prospects [2].

Core Point - The order being signed does not legalize marijuana or sanction its use as a recreational drug, emphasizing that it is not related to future legalization efforts [1] Group 1 - The statement highlights the distinction between the order and the legalization of marijuana, clarifying that it does not endorse recreational use [1]

Core Points - President Trump signed an executive order to reclassify marijuana as a Schedule III drug, easing some federal restrictions and allowing for more research opportunities [1][3] - The reclassification is aimed at addressing the medical needs of individuals suffering from extreme pain and incurable diseases, positioning marijuana as a substitute for opioid painkillers [2][4] - Marijuana stocks experienced a surge in value following rumors of the executive order prior to its announcement [3] Industry Impact - The reclassification could provide tax relief for marijuana businesses in states where the substance is already legalized, potentially boosting the industry [2] - Trump's campaign for a third term in 2024 indicates a shift towards a more favorable stance on marijuana, suggesting future legislative support for the industry [4][5] - The executive order does not fully legalize marijuana but represents a significant step towards more lenient regulations, which could enhance market conditions for marijuana-related businesses [1][4]

Core Viewpoint - The executive order signed by President Trump represents a significant shift in U.S. cannabis policy, reclassifying marijuana from Schedule I to Schedule III, which could have major implications for the cannabis industry and its financial landscape [1][2]. Industry Impact - The reclassification is seen as a financial lifeline for the cannabis industry, allowing companies to deduct standard expenses like rent and payroll for the first time due to exemption from IRS Code Section 280E [6]. - The move is expected to facilitate banking access and attract institutional capital that has previously been deterred by compliance concerns [6]. - Analysts anticipate that the changes, along with the Medicare pilot program, may draw major pharmaceutical companies into the cannabis sector to pursue federally insured revenue [6]. Market Reaction - Following the announcement, shares of cannabis companies showed mixed results: Tilray Brands increased by approximately 6%, while Trulieve and Green Thumb Industries saw declines of about 15% and 5%, respectively. The AdvisorShares Pure US Cannabis ETF fell by more than 10% [5]. Regulatory Developments - The Centers for Medicare and Medicaid Services is set to launch a pilot program allowing certain Medicare-covered seniors to receive free, doctor-recommended CBD products, which must comply with local and state laws [4]. - The executive order does not legalize marijuana for recreational use, but it may encourage further research into the effects of CBD [8]. Consumer Trends - CBD has gained popularity in various consumer goods, but the FDA has not fully endorsed the compound, citing inconsistent benefits and potential risks associated with prolonged use [7].

Core Viewpoint - U.S. President Donald Trump plans to direct the U.S. Department of Justice to reclassify cannabis as a less dangerous drug, which could significantly impact the cannabis industry and consumers shopping at dispensaries [1] Group 1: Impact on Cannabis Classification - The reclassification of cannabis could lead to changes in legal status, potentially increasing accessibility for consumers [1] - A less dangerous classification may encourage more research and development in cannabis-related products [1] - This move could influence state-level regulations and the overall market dynamics of the cannabis industry [1] Group 2: Implications for Consumers - Consumers may experience a broader range of products available at dispensaries due to the reclassification [1] - The change could lead to lower prices and increased competition among cannabis retailers [1] - Enhanced consumer confidence in cannabis products may result from the new classification [1]

U.S. President Donald Trump on Thursday said he would sign an order recommending the loosening of federal regulations on marijuana, a move that could further reverse decades of tough-on-weed policy. ...